Relationship of Fungal Vaginitis Therapy to Prior Antibiotic Exposure by Glover, Douglas D. & Larsen, Bryan
Relationship of fungal vaginitis therapy to prior antibiotic
exposure
Douglas D. Glover1 and Bryan Larsen2
1Professor of Obstetrics and Gynecology, West Virginia University Medical Center, Morgantown, WV
2Dean for University Research, Des Moines University-Osteopathic Medical Center, 3200 Grand Avenue,
Des Moines, IA
Objective: To address the putative association of antibiotic use and subsequent yeast vaginitis in a population of
non-pregnant women.
Methods: Three hundred and sixteen women who received medical care in rural family medicine clinics enrolled
in this study. Participants were pre-menopausal and non-pregnant and were followed until they used a course of
antifungal therapy for vaginitis, became pregnant or moved from the catchment area. At entry subjects were free
of vaginitis symptoms and had taken no antibiotics for 30 days.
Patients were followed by repeated review of clinic records, hospital records and telephone or personal inter-
views. Data collection included documentation of episodes of antifungal treatment for vulvovaginal candidiasis and
confirmed antibiotic treatment or credible history of antibiotic use prior to the use of antifungal therapy.
Physician-reported uses of antibiotic and antifungal as well as patient-reported uses of these were recorded.
Results: There were four reported cases of antifungal therapy following within a month of antibiotic use, in
contrast to 484 antibiotic uses not followed by antifungal use. If time of observation was extended to 6 months
from antibiotic use, there were 13 uses of antifungal therapy after antibiotics and 475 uses of antibiotics not
followed by antifungal therapy.
Conclusion: Our results cast doubt on the association of antibiotics as a putative cause of yeast vulvovaginitis.
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A commonly held opinion among gynecologists is
that antibiotic therapy predisposes women to
development of symptomatic vulvovaginal yeast
infection. A previous examination of this issue
among a cohort of pregnant women indicated
that while vaginal colonization is a risk factor for
subsequent development of symptomatic yeast
vaginitis, antibiotic therapy – even intensive
therapy – is not associated with an increased risk
of developing symptoms1. It might be argued
this lack of association was obscured by an
increased risk of yeast colonization and
symptomatic infection associated with pregnancy.
Consequently, we undertook an observational
study to address the putative association of anti-
biotic use and yeast vaginitis in a population of
non-pregnant women.
METHODS
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 2003 The Parthenon Publishing Group 157Subjects approved this prospective observational
study of the association of antibiotic treatment
history and subsequent treatment for vulvovaginal
candidiasis. Participants for this study were drawn
from women who received their medical care at
four Family Medicine clinics in Northern West
Virginia and Southwest Pennsylvania. One
hundred and eighty-four women followed in this
study were identified from participants of a prior
study of antibiotic use and vulvovaginitis in
pregnancy1 and were 6 weeks postpartum at the
time of entry into the study. An additional 132
women who received their care in these clinics
were also enrolled for a total of 316 participants.
All participants were pre-menopausal and non-
pregnant at the time of entry into the study and
were followed at least until they used a course of
antifungal therapy for vaginitis, became pregnant
or moved from the catchment area. Some patients
remained in the study through more than one
course of antifungal treatment. No patients asked
toprematurelyendtheirparticipationinthestudy.
The study population had limited options for
medical care so that virtually all antibiotic
prescriptions were recorded in the records of these
patients. Few moved out of the catchment area
during the study. None of the participants had
vaginal symptoms at the time they entered
the study and none had taken antibiotics within
30 days of entering the investigation. Patients
in this study were followed for an average of
101 weeks (range, 5–208 weeks).
Patients were followed by repeated review of
clinic records, hospital records when appropriate
and telephone or personal interviews conducted
by the investigator (DDG) or study nurse at
intervals of 6 months or less. Data sought included
documentation of episodes of antifungal treatment
for vulvovaginal candidiasis and confirmed anti-
biotic treatment or credible history of antibiotic
use prior to the use of antifungal therapy.
Additional information on these patients was
derived from the patient records. We recorded
both physician-reported uses of antibiotics and
antifungals as well as patient-reported uses of
antibiotics and antifungals and requested that
patients supply the used medicine packages
whenever possible, to increase the reliability of
patient-reported histories.
RESULTS AND DISCUSSION
We followed 316 women for an average of 101
weeks and found that many were treated with
antibiotics for a variety of indications during the
study. The 316 individuals enrolled used 488
courses of antibiotics while being followed in
this investigation. Only 46 individuals (14.5%)
reported any use of antifungal therapy for vaginitis
and these women used 79courses of antifungal
therapy for an annualized rate of 0.51 presumed
cases per year. The majority of antifungal use
represented self-treatment (46 uses) and the
remainder were prescribed by physician or
physician’s assistant (33 uses). Some of the patients
candidly reported that their use of antifungal
therapy was not the result of symptoms but was
based on their belief that they would develop a
yeast infection after taking an antibiotic.
Those who used antifungal therapy had a
history of 97 courses of antibiotics (an average of
2.11 antibiotic uses per patient) whereas the 270
who did not use antifungal drugs reported 391
courses of antibiotics (an average of 1.45 uses per
patient) and over all, 29% of women who had a
history of antibiotic use also used antifungal
therapy, compared to 19% antifungal use among
non-antibiotic-treated women (not significant by
the Chi-square test). The time of observation was
not identical for all patients, therefore when we
compared antifungal use on an annualized
basis, the rate was 13.8% per year use among
antibiotic-treated women versus 11.5% antifungal
use per year among those not using antibiotics.
These observations did not distinguish between
antibiotic use proximate to the antifungal use
versusantibioticusenottemporallyassociatedwith
the use of antifungal therapy. Other studies1,4 have
considered antibiotic use within approximately
1 month to have relevance to subsequent yeast
vaginitis. Therefore we grouped our findings
according to antibiotic use within 1 month or
6 months prior to the antifungal use. Table 1
reports antifungal use as the index event and
because the antifungal therapy may have repre-
sented self-treatment rather than physician-
supervised use, we have indicated which cases
represent self-treatment. From this information it
is clear that only 12% of physician-supervised
courses of antifungal therapy were prescribed
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antibiotic use greater than 6 months prior to
antifungal therapy may be considered as irrelevant
to yeast vaginitis, 64% of physician-supervised
antifungal therapy events and 84% of all uses of
vaginal antifungal treatment were not temporally
related to prior antibiotic use.
When all antibiotic use was evaluated, it may be
noted that there were four occurrences of anti-
fungal therapy following within a month of
antibiotic use, in contrast to 484 antibiotic uses
not followed by antifungal use. If the time of
observation is extended to 6 months from the
index antibiotic use, there were 13 uses of anti-
fungal therapy after antibiotics and 475 uses of
antibiotics not followed by antifungal therapy.
A closer examination of the records of the four
cases of antifungal use within a month of receiving
antibiotic revealed that one patient received an
intramuscular injection of ceftriaxone followed by
10 days of oral metronidazole and developed
vaginal symptoms 1 day after the metronidazole
treatment ended. She did not have an examination
to verify the etiology of her vaginal symptoms.
A second individual used timethoprim–
sulfamethoxazole for 20 days and developed
vaginal symptoms 6 days post-therapy. A third
patient developed symptoms on the 12th day of a
combined regimen of amoxicillin (10 days) and
doxycycline (14 days). The fourth individual
developedsymptoms29daysafterasingle2 gdose
of metronidazole. The latter three cases had
yeast-positive wet mounts to document the
etiology of infection.
This study was not culture-based and did not
include a definitive diagnosis of yeast vaginitis.
Rather, to attain a larger study population we
chose to employ patient use of vaginal antifungal
therapy as a surrogate for definitive diagnosis. This
would probably overestimate the rate of yeast
vaginitis that theoretically would also tend to
overestimate any relationship between antibiotic
use and yeast vaginitis. While our prospective
evaluation of this population could not prove that
some cases of yeast vaginitis might be elicited by
prior antibiotic treatment, the vast majority of
antibiotic uses were not followed by a need for
antifungal therapy.
We have previously noted that the concept of
antibacterial drugs eliciting yeast vaginitis is
commonly repeated in textbooks and ingrained in
the thinking of physicians who may vividly recall
patients who received an antibiotic prior to
developing vaginal symptoms. Furthermore, the
concept of a protective role for the vaginal flora is
intellectually compelling. However, the literature
supporting the concept of antibiotics predisposing
to yeast vaginitis is limited to a relatively few
reports. Caruso2 reported that tetracycline treat-
mentwasassociatedwithanincreaseinthepercent
of women colonized by yeast. A similar result was
obtained by Oriel and Waterworth3 who studied
tetracycline and minocyline which provided
similar results. Some of the women acquiring yeast
in these studies also became symptomatic. For
example,inonereport,after14daysoftetracycline
the colonization rate increased from 13% to 29%
although fewer than half the patients remained in
the study. Of the 14 women who were culture
positive for yeast, four were reported to have
vaginitis3 and it was also noted that two of the
women in the study went from culture positive to
culture negative during 2 weeks of tetracycline
therapy. They concluded that only a minority of
those who had increased yeast colonization actu-
ally developed symptoms. One of the four women
in our study who used vaginal antifungal therapy
after antibiotic had been treated with tetracycline.
In contrast, 20 women received tetracycline
therapy without developing vaginal symptoms.
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Interval from
antibiotic use
to antifungal
treatment
Courses of
antifungal
treatment
Courses
supervised
by physician
Average time
of observation
(months)
1 month or less
1 to 6 months
> 6 months
No antibiotic
Total
4*
9
41
25
79
4**
8
3
18
33
118
110
124
89
101
*One patient self-treated with an antifungal during antibiotic
therapy. This patient was not included in this table because we
could not state that antibiotic was used prior to antifungal therapy.
**Two patients were treated concurrently with antibiotic
treatment by a physician’s assistant at the patient’s request; also
not included in the total
Table 1 Antibiotic use prior to antifungal therapy for
yeast vaginitisThe extent to which antibiotics other than
tetracycline may affect mucocutaneous yeast is
unclear. While our results did not show any
consistentincreaseinantifungalusewithantibiotic
use, a study by MacDonald and co-workers4, who
alsousedprescriptionofantifungaldrugsasasurro-
gate measure of vaginal candidiasis, did show an
increase in yeast vaginitis and they also reported
that cephalosporins were associated with the
greatest attributable risk in these women. Among
the13womenwhousedantifungaltherapywithin
6 months of antibiotic treatment only two were
treated with a cephalosporin and these were not
per oral medication.
The concept that antibiotics, particularly per
oral preparations, generally predispose to vaginal
yeast infection will probably remain medical
dogma,butourresultscastdoubtonthestrengthof
this association.
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